Elevance Looks Cheap Now: But is it Time to Buy or Dodge?
Elevance Health, Inc. ELV, a leading U.S. health benefits provider, appears to be trading at a discount. Its forward 12-month P/E ratio stands at just 10.35X, significantly below its five-year median of 13.46X and the industry average of 13.86X. Compared to peers, UnitedHealth Group Incorporated UNH and Humana Inc. HUM, which trade at 12.06X and 14.73X, respectively, ELV looks attractively valued. It currently holds a Zacks Value Score of A, highlighting strong valuation fundamentals.
But is this discount a sign of hidden opportunity, or a red flag? Let's explore the drivers behind Elevance's valuation and its long-term outlook.
Image Source: Zacks Investment Research
Headquartered in Indianapolis, Elevance is well-positioned for sustained growth, underpinned by strategic initiatives across its commercial and government segments. Elevance continues to see steady growth in its commercial segment. In 2024, risk-based and fee-based commercial memberships grew 4.6% and 1% year-over-year. Its Individual Commercial business is especially strong, reporting a 14.2% surge in the first quarter of 2025 alone.
By exiting underperforming markets, Elevance has streamlined its government business, improving overall efficiency. It also has room to expand its Medicare Advantage footprint in underpenetrated states, which could unlock future growth.Vision and dental memberships continue to witness growing momentum.
With a Return on Invested Capital of 9.94%, far above the industry average of 5.79%, Elevance demonstrates superior capital deployment. Its $84.1 billion market cap gives it the scale to pursue strategic acquisitions and reallocations toward higher-margin businesses.
ELV remains committed to returning capital to shareholders. In the first quarter of 2025 alone, it repurchased $880 million worth of shares and had $8.4 billion remaining under its buyback authorization. Its dividend yield of 1.82% also exceeds the industry average of 1.40%.
Despite headwinds in the broader market, ELV shares have gained 1.9% year to date, outperforming both the industry and the S&P 500. In contrast, UnitedHealth and Humana have posted declines, reflecting broader sectoral pressure.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Elevance's 2025 and 2026 EPS implies a 4.2% and 13.8% uptick, respectively, on a year-over-year basis. The estimates remained stable over the past week. Moreover, the consensus mark for 2025 and 2026 revenues suggests an 11.2% and 7.1% increase, respectively.
The company beat earnings estimates in three of the past four quarters and missed once. This is depicted in the figure below.
Elevance Health, Inc. price-eps-surprise | Elevance Health, Inc. Quote
Despite its strengths, Elevance faces some notable challenges. A key concern is the decline in Medicaid and Medicare Supplement membership, leading to both overall membership losses and reduced revenues. A drop in government funding could put additional pressure on profitability.
Increasing medical costs pose a massive challenge as industry players continue to struggle with rising utilization and squeezing margins. The company's benefit expense ratio, measuring the portion of premiums spent on claims, has been increasing, rising from 87% in 2023 to 88.5% in 2024. Our estimate suggests it could reach 88.7% in 2025, signaling further pressure on earnings.
Policy shifts such as the Most Favored Nation drug pricing model introduced by the Trump administration have rattled the Pharmacy Benefit Management (PBM) industry. With major PBM exposure, Elevance — like UnitedHealth, CVS and others — faces uncertainty in this space.
Elevance Health offers an appealing valuation and demonstrates strong fundamentals in its commercial business, capital efficiency and shareholder returns. However, ongoing pressures from rising medical costs, government program headwinds, and regulatory uncertainties temper the bullish case.
With a Zacks Rank #3 (Hold), the stock reflects a balanced risk-reward profile. It may not be a screaming buy at the moment, but it remains a solid name to watch, especially for long-term investors seeking stability, value and consistent execution in the healthcare space. Patience may be warranted until clearer signals on regulatory outcomes emerge.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report
Humana Inc. (HUM) : Free Stock Analysis Report
Elevance Health, Inc. (ELV) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Feds demand Oregon Health Plan data in crackdown against immigrant coverage
PORTLAND, Ore. (KOIN) – Federal officials are seeking the personal data of the Medicaid-funded Oregon Health Plan as part of a crackdown on coverage for undocumented immigrants. The request, as first reported by , comes after the Department of Homeland Security provided immigration officials with similar data from California, Illinois, Washington state and Washington, D.C. 'Just wrong': Oregon advocates say SCOTUS decision targets transgender youth Oregon, like these states, has expanded medical coverage to undocumented residents through state-funded programs. On Monday, Gov. Tina Kotek said her office is reviewing the order. 'I think it's very important, to a degree that we can, that we do not share personal information,' Kotek said. 'Always comfortable with aggregated information, but when we start sharing personal medical information that could be misused, that's a challenge for me.' The state of Oregon has until the end of July 2025 to comply. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
2 hours ago
- Yahoo
Why Applied Optoelectronics Stock Skyrocketed Today
Applied Optoelectronics stock rocketed higher Friday thanks to new financing disclosures from the company. The tech specialist announced that one of its subsidiaries had taken on a new loan that was used to pay a previously existing loan. News of the refinancing move follows an announcement that the company recently made a major product shipment to a hyperscaler customer. 10 stocks we like better than Applied Optoelectronics › Applied Optoelectronics (NASDAQ: AAOI) stock soared higher again in Friday's trading. The tech specialist's share price rose 18.6% in the daily session despite a 0.2% decline for the S&P 500 (SNPINDEX: ^GSPC) and a 0.5% fall for the Nasdaq Composite (NASDAQINDEX: ^IXIC). Applied Optoelectronics' valuation surged today thanks to news that one of the company's subsidiaries had reworked previously existing debt agreements. The stock climbed roughly 39% over the last week of trading. After the market closed on Wednesday, Applied Optoelectronics submitted a filing to the Securities and Exchange Commission (SEC) revealing two significant financing changes for its Global Technology subsidiary. Because the stock market was closed for the Juneteenth federal holiday on Thursday, the investor reaction to the new disclosures was pushed into today's trading. As per the filing with the SEC, Applied Optoelectronics' Global Technology has entered into a one-year credit agreement with China Construction Bank totaling 96.8 million Chinese renminbi -- which works out to roughly US$111.55 million based on the current exchange rate. Applied Optoelectronics said that the funding from the new agreement had been used to pay back other outstanding loans with Shanghai Pudong Development Bank. Despite this week's rally, Applied Optoelectronics stock is still down roughly 36% across the year due to uneven business performance and concerns about the company's financing. On the other hand, the company has recently announced significant shipments for its high-speed data center transceivers for a major data center customer. Along with some indications that the company could see an increase in demand powered by artificial intelligence (AI) initiatives from cloud hyperscaler customers, the recently announced financing moves suggest that the company has a found a near-term solution to some of its financing challenges. Before you buy stock in Applied Optoelectronics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Applied Optoelectronics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Applied Optoelectronics Stock Skyrocketed Today was originally published by The Motley Fool
Yahoo
5 hours ago
- Yahoo
Republicans balk at changes to Trump tax bill as deadline nears
WASHINGTON — Senate Republican leaders are in crunch time as they attempt to get all corners of their party to agree on key provisions of President Donald Trump's signature tax bill. The Senate Finance Committee released its long-awaited tax portion of the reconciliation bill on Monday, making a number of changes to the version passed by their House colleagues last month. However, those changes have not been met with open arms by several in the GOP conference — which could threaten its passage if Senate leaders bring it to the floor for a vote next week. One of the thorniest issues tucked into the latest iteration is a proposal to lower the Medicaid provider tax to 3.5%, far below the current 6% tax. That has raised concerns among some lawmakers from states they say rely on that tax to provide health coverage. Medicaid provider taxes are taxes placed by states on medical providers like hospitals and clinics that then boost reimbursement from the federal government. Sen. Susan Collins, R-Maine, has been a vocal opponent to paring back the tax, although she declined to elaborate on her current stance. However, Sen. Josh Hawley, R-Mo., expressed his frustration with the proposal, arguing it would disadvantage rural hospitals. 'I've talked to our leadership constantly about this. And I was told, we've got a fix on the provider tax issue, we're gonna help rural hospitals,' Hawley told reporters on Tuesday. 'There's nothing in here for rural hospitals. In fact, what they're doing is lowering the provider tax to make it even worse.' It's not clear if that language will be amended before it's voted on. Senate Finance Chair Mike Crapo, R-Idaho, said on Tuesday they are 'vetting' the text. Dr. Mehmet Oz, the administrator for the Centers for Medicare and Medicaid Services, met with Senate Republicans during their weekly lunch on Tuesday to assuage any concerns on proposed cuts. When asked if there is any chance Republicans will change language related to the provider tax, Oz brushed off those concerns. 'Well, the details of the language are up to the leadership, but the specifics, the framework of addressing the legalized money laundering with state-directed payments and provider taxes must be in this bill,' Oz said. 'It should be in this bill.' Vice President JD Vance also attended the lunch, telling reporters they would 'work through' any concerns with the current language related to Medicaid. 'If we can't address that concern in your preferred way, is there another way that we can fix it,' Vance told reporters. 'That's just part of the legislative process' Meanwhile, Sen. Lisa Murkowski, R-Alaska, predicted: 'I don't think it's going to stay in this form.' One of the other politically potent issues tucked into the reconciliation bill is the proposed expansion of federal deductions for state and local taxes paid, also known as SALT. While House Republicans proposed increasing the cap to $40,000 — with some income limits — the Senate lowered that number to just $10,000, which is the cap currently in place. That provision has already been rejected by the SALT Caucus in the House, which has enough lawmakers to tank the bill if they don't get their requested amount. Crapo said those provisions would continue to be worked out in the Senate and the House, acknowledging 'that's a very big piece, obviously.' 'We will work it out,' Crapo said. Republican leaders must also deal with Sen. Rand Paul, R-Ky., who has said he would vote against the package so long as it contains language raising the debt ceiling. The Senate version includes language to raise the debt limit to $5 trillion, even higher than the $4 trillion ceiling proposed by the House. 'We roll around to 2026 elections, what are they going to say? 'Oh Democrats, you know, they're for borrow and spend,'' Paul said on Tuesday. 'But now the Republicans will have joined the Democrats in being for borrow and spend.' The text release starts the clock for senators to finalize the package, get it approved by the Senate parliamentarian, and vote on the measure before the end of next week to meet Republicans' self-imposed deadline of July 4. The parliamentary process could take several days as each provision must be reviewed by the Senate adviser to ensure they adhere to the strict rules of reconciliation. Once the package passes the Senate, it will then be returned to the House for consideration. From there, Republicans will likely need to convene what is known as a conference committee between House and Senate leaders to negotiate a compromise package in order to avoid a legislative tennis match.
